Hims & Hers Health Inc. Aktie News

Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings

Hims stock landed in hot water this month after Novo Nordisk slammed the telehealth giant with a lawsuit over its knockoff obesity drug.

AI is crushing digital businesses, and capital is starting to rotate out of tech. Meanwhile, many REITs trade at 30% discounts to NAV with ~5% yields. We highlight three anti-AI real asset plays that could rerate sharply higher.

Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30 as of February 13.

Hedge fund bets against Hims & Hers Health hit their highest in at least a year in January, just before the online telehealth firm clashed with Novo Nordisk over its cut-price weight-loss pill, according to data shared with Reuters by Hazeltree.

AI panic crushed SaaS and dragged down BDCs and asset managers. Trading at steep discounts and high dividend yields, we think that this is a historic opportunity. We explain why the market got it wrong and highlight rare opportunities to potentially win big.

The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, attorneys and other experts told Reuters.

HIMS Selloff Creates De-Risked Entry